Do you know when, how and on which patients to use ferric carboxymaltose to treat heart failure?
Iron deficiency can have a negative impact on both mitochondrial and cardiac function and on the structure of the heart, this can lead to heart failure. Ferric carboxymaltose can improve both cardiac structure and performance.
Led by moderators Chan Hong (Singapore) and Franco Cheng (Hong Kong), it includes a speaker presentation from David Sim (Singapore) and a discussion from panellists Maurizio Volterrani (Italy) and Daniel Lighezan (Romania) that will examine the importance of ferric carboxymaltose, through consideration of real-world examples, live discussions and audience Q&A.
To evaluate and understand the importance of iron in Heart Failure
To evaluate and understand when and how to use ferric carboxymaltose in Heart Failure
To apply evidence-based recommendations to two real world cases
Cardiovascular team members – Doctors, nurses and Pharmacists
Cardiovascular pharmacotherapy researchers
David Sim, Maurizio Volterrani, Daniel Lighezan
Chan Hong, Franco Chen
Ferric Carboxymaltose: Ironing Out the Issues Around Heart Failure Related Readmissions